Every 8-K that PROTOKINETIX INC (PKTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PKTX filings page.
ProtoKinetix, Inc. reported several corporate updates. Longtime director Edward McDonough resigned from the board, stating his decision was not due to any disagreement with the company. The board then appointed Michael Jones and Jason Lamp as new directors, and named translational scientist Dr. Keith Brunt as both a director and president.
The company formed a wholly owned subsidiary, SightPath Biotech LLC, to develop its PKX-001 synthetic glycopeptide for dry-eye disease and other ocular conditions. Two independent analyses in 2021 and 2025 estimated the present value of related patents and development work at approximately $253 million, reflecting factors such as novel IP, market size, and competitive position.
ProtoKinetix disclosed that it filed Form 12b-25 notices for delayed filing of its 2025 annual report and first-quarter 2026 quarterly report and is working on completing these filings. The board also approved repricing options covering 61,190,000 shares and warrants for 6,000,000 shares from a $0.028 to $0.01 exercise price and extended their expiration dates by two years.
ProtoKinetix, Incorporated furnished a company update to its stockholders. The update was distributed by the company and is included as Exhibit 99.1 to this report, where the full text can be read.
The information is provided under a Regulation FD disclosure, meaning it is intended to share information with all investors at the same time. The company specifies that this material is being furnished rather than filed, so it is not automatically incorporated into other securities law filings.
ProtoKinetix, Incorporated (PKTX) filed an amended Form 8-K to update a prior current report. The Amendment corrects the Company’s contact telephone number and attaches a revised version of a press release that was posted on the Company’s website on November 17, 2025.
The updated press release is furnished as Exhibit 99.1 under Regulation FD Disclosure and is not treated as filed for liability purposes or incorporated by reference into other securities law filings. No financial results, business strategy, or transactional details are changed by this Amendment.
ProtoKinetix, Inc. announced a major leadership change following the unexpected death of its long-time President and Chief Executive Officer, Clarence E. Smith, in an accident on November 13, 2025. Smith had led the company’s management and served on its Board of Directors for many years.
Under the company’s bylaws, sole remaining director Ed McDonough appointed Michael Guzzetta as Chairman of the Board, President, and Chief Executive Officer on November 16, 2025. Guzzetta will also continue in his existing roles as Chief Financial Officer, Secretary, and Treasurer, resulting in one individual holding all principal executive and financial positions. His compensation under his existing employment agreement has not been changed. The company furnished a press release on November 17, 2025 to formally announce these leadership changes.
ProtoKinetix, Incorporated received stockholder approval by written consent to amend its Articles of Incorporation to increase the total number of authorized common shares from 500,000,000 to 600,000,000. The amendment became effective after sufficient consents were received by 5:00 p.m. Eastern Time on October 6, 2025.
As of the September 5, 2025 record date, there were 389,080,152 shares of common stock outstanding and entitled to 389,080,152 votes, and stockholders holding 57.1% of the outstanding common shares consented to the action.